StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MEDICAB.MX$61.90+2.48%
Fair $61.90+0.0%

MEDICAB.MX

Médica Sur, S.A.B. de C.V.

Healthcare / Medical Care FacilitiesMexico

$61.90

+1.50 (+2.48%)

Fairly Valued+0.0%Fair Value $61.90Fund rank 35/100 · Data gapFallback financials|
SA 66/B
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $525.8M · quality 72.7/100

Data gap 35/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 75/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

66/100

B

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · MEDICAB.MXLocal privado en este navegador · Médica Sur, S.A.B. de C.V.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5.7B

P/E

12.4x

↓

EV/EBITDA

5.6x

↓

ROE

21.4%

↑

Gross Margin

35.8%

↓

Debt/Equity

0.40

↑
52-Week Range$62
$42$62

TradingView lightweight chart

MEDICAB.MX price, volumen y niveles de valoración

Último $62.00Periodo +3000.0%
Fair value: $61.90

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+7.4%

FCF CAGR

+45.2%

FCF margin

16.8%

FCF / Net income

1.49x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $4.79B · net income $540.2M · FCF $802.8M

2022-FY → 2025-FY

Gross margin

35.8%+0.5% pts

Operating margin

16.8%+1.9% pts

Net margin

11.3%-13.3% pts

FCF margin

16.8%+10.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$4.79B$4.79B$4.40B$4.13B$3.87B
Net Income$540.2M$540.2M$461.5M$635.0M$949.8M
EBITDA$1.11B$1.11B$863.9M$995.5M$922.8M
EPS5.005.004.305.888.80
Gross Margin35.8%35.8%33.9%35.3%35.3%
Operating Margin16.8%16.8%12.9%14.3%14.9%
Net Margin11.3%11.3%10.5%15.4%24.6%
Balance Sheet
Debt/Equity0.400.400.440.510.41
Current Ratio1.691.69———
Cash Flow
Free Cash Flow$802.8M$802.8M$525.8M$429.2M$262.2M
Returns
ROE21.4%21.4%19.7%31.2%37.7%
Valuation
P/E12.3812.387.866.914.32
EV/EBITDA5.555.554.094.734.24
P/B2.652.651.552.151.63
Growth & Yield
Revenue Growth8.8%8.8%6.6%6.8%—
EPS Growth16.3%16.3%-26.9%-33.2%—
Dividend Yield2.6%2.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

3.2%

fácil

EPS terminal req.

$5.49

Spread vs growth

13.1%

5Y implied EPS CAGR

5.9%

razonable

EPS terminal req.

$6.65

Spread vs growth

10.4%

10Y implied EPS CAGR

7.9%

razonable

EPS terminal req.

$10.70

Spread vs growth

8.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +43.5%

Total return

+43.5%

Start / end P/E

10.2x → 12.4x

EPS bridge

4.30 → 5.00

Residual

+3.4%

EPS growth+16.3%
Multiple rerating+21.2%
Dividend+2.6%
Residual / FX / buybacks / cross-term+3.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.